PURPOSE: To review our experience in the management of malignant transformation of teratoma (MTT). MATERIALS AND METHODS: Nine patients with MTT were identified from January 1980 to August 2005, with all pathological specimens re-reviewed by a single genitourinary pathologist. RESULTS: Two patients presented with clinical stage I disease in which malignant transformation occurred within the primary testis tumor (rhabdomyosarcoma in 1 and adenocarcinoma in 1). These patients underwent a primary retroperitoneal lymph node dissection (RPLND). No viable tumor was identified in the specimen, and both patients were alive without disease at 16 months follow-up. Of the remaining 7 patients, the clinical stages were IIA (N = 1), IIB (N = 3), and III (N = 3), and all were treated with chemotherapy followed by RPLND. The MTT histology of these RPLND specimens consisted of adenocarcinoma (N = 3), rhabdomyosarcoma (N = 2), angiosarcoma (N = 1), and astrocytoma (N = 1). Following preoperative chemotherapy, a significant radiologic response (defined as more than a 25% reduction in maximum tumor circumferential diameter) was demonstrated in 1 patient, and normalization of serum tumor markers was demonstrated in 6. At a mean follow-up of 5 years, 3 of these 7 patients were alive with no evidence of disease, 1 had persistent disease, and 3 had died of disease, and their median disease-specific survival duration was 4.6 years. CONCLUSIONS: In our experience, MTT is significantly resistant to current chemotherapeutic regimens, as demonstrated by its poor radiologic response to treatment. Alternative therapeutic strategies targeted to MTT are thus needed.
PURPOSE: To review our experience in the management of malignant transformation of teratoma (MTT). MATERIALS AND METHODS: Nine patients with MTT were identified from January 1980 to August 2005, with all pathological specimens re-reviewed by a single genitourinary pathologist. RESULTS: Two patients presented with clinical stage I disease in which malignant transformation occurred within the primary testis tumor (rhabdomyosarcoma in 1 and adenocarcinoma in 1). These patients underwent a primary retroperitoneal lymph node dissection (RPLND). No viable tumor was identified in the specimen, and both patients were alive without disease at 16 months follow-up. Of the remaining 7 patients, the clinical stages were IIA (N = 1), IIB (N = 3), and III (N = 3), and all were treated with chemotherapy followed by RPLND. The MTT histology of these RPLND specimens consisted of adenocarcinoma (N = 3), rhabdomyosarcoma (N = 2), angiosarcoma (N = 1), and astrocytoma (N = 1). Following preoperative chemotherapy, a significant radiologic response (defined as more than a 25% reduction in maximum tumor circumferential diameter) was demonstrated in 1 patient, and normalization of serum tumor markers was demonstrated in 6. At a mean follow-up of 5 years, 3 of these 7 patients were alive with no evidence of disease, 1 had persistent disease, and 3 had died of disease, and their median disease-specific survival duration was 4.6 years. CONCLUSIONS: In our experience, MTT is significantly resistant to current chemotherapeutic regimens, as demonstrated by its poor radiologic response to treatment. Alternative therapeutic strategies targeted to MTT are thus needed.
Authors: Andrew J Stephenson; George J Bosl; Robert J Motzer; Michael W Kattan; Jason Stasi; Dean F Bajorin; Joel Sheinfeld Journal: J Clin Oncol Date: 2005-04-20 Impact factor: 44.544
Authors: R J Motzer; A Amsterdam; V Prieto; J Sheinfeld; V V Murty; M Mazumdar; G J Bosl; R S Chaganti; V E Reuter Journal: J Urol Date: 1998-01 Impact factor: 7.450
Authors: Alessia C Donadio; Robert J Motzer; Dean F Bajorin; Philip W Kantoff; Joel Sheinfeld; Jane Houldsworth; Raju S K Chaganti; George J Bosl Journal: J Clin Oncol Date: 2003-12-01 Impact factor: 44.544
Authors: Mounsif Azizi; Ahmet M Aydin; Salim K Cheriyan; Charles C Peyton; Matthew Montanarella; Scott M Gilbert; Wade J Sexton Journal: Transl Androl Urol Date: 2020-01
Authors: Mariëtte E G Kranendonk; Wenzel M Hackeng; G Johan A Offerhaus; Folkert H M Morsink; Geertruida N Jonges; Gerard Groenewegen; Pieter-Jaap Krijtenburg; Heinz-Josef Klümpen; Wendy W J de Leng; Leendert H J Looijenga; Lodewijk A A Brosens Journal: Diagn Pathol Date: 2020-07-25 Impact factor: 2.644